Welcome to our dedicated page for United Therapeutics SEC filings (Ticker: UTHR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
United Therapeutics Corporation filings document an operating biotechnology company with Nasdaq-listed common stock and a public benefit corporation structure. Recent 8-K reports cover quarterly and annual operating results, business updates, clinical-study announcements for Tyvaso and ralinepag, and capital actions such as share repurchase programs and accelerated share repurchase agreements.
Proxy materials describe board elections, director changes, executive compensation, shareholder voting matters and governance practices. The company’s formal disclosures also address its treprostinil-centered pulmonary arterial hypertension business, development programs in pulmonary and transplant-related medicine, and common-stock capital structure.
United Therapeutics Corp Chairperson & CEO Martine Rothblatt reported an option exercise and related share sales. On June 9, 2026, she exercised 9,500 stock options for common stock at an exercise price of $146.03 per share, then sold 9,500 common shares in a series of open‑market transactions at weighted average prices around $545–$553 per share.
The filing notes these transactions were carried out under a pre‑arranged Rule 10b5-1 trading plan adopted on November 7, 2025, which is scheduled to continue until the earlier of exercising 1,734,410 stock options that expire on March 15, 2027 or December 31, 2026. After these trades, the report shows 50,013 common shares held directly, along with additional indirect holdings through various family trusts and by a spouse, and 69,410 stock options remaining from the reported option grant.
United Therapeutics Corp CFO and Treasurer James Edgemond reported an options exercise and related share sales in company common stock. On June 8, 2026, he exercised 10,000 stock options at an exercise price of $117.76 per share to acquire 10,000 shares.
That same day, he sold 10,000 common shares in a series of open‑market transactions at weighted average prices ranging from the mid‑$540s to low‑$550s per share. According to the filing, these trades were made under a pre‑arranged Rule 10b5‑1 trading plan entered into on October 31, 2025.
Following these transactions, Edgemond directly holds 18,876 shares of United Therapeutics common stock, and the filing shows no remaining derivative (stock option) position tied to this grant.
UNITED THERAPEUTICS (UTHR) Chairperson & CEO Martine Rothblatt reported an exercise-and-sell transaction in company stock. On June 8, 2026, she exercised 9,500 stock options at an exercise price of $146.03 per share and sold 9,500 shares of common stock in multiple open-market trades at prices generally around $545–$551 per share. These transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025. Following the transactions, she held 50,013 shares of common stock directly, in addition to several indirect holdings through family trusts and shares held by her spouse.
United Therapeutics Corp Chairperson & CEO Martine A. Rothblatt reported an exercise-and-sale transaction in company stock. On June 5, 2026, she exercised 9,500 stock options at an exercise price of $146.03 per share and received an equal number of common shares.
The same day, she sold 9,500 shares of common stock in open-market trades, with footnotes stating prices ranged from $545.345 to $550.58 per share, under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025. Following these transactions, she directly holds 50,013 shares of common stock and indirectly holds additional shares through family trusts and a spouse account, while retaining 88,410 stock options expiring on March 15, 2027.
UNITED THERAPEUTICS Corp CFO and Treasurer James Edgemond reported a combination of option exercise and share sales in company stock. He exercised stock options covering 10,000 shares of Common Stock at a strike price of $117.76 per share and, on the same date, executed open-market sales totaling 10,000 shares of Common Stock.
The sales were broken into multiple trades at weighted average prices generally in the mid‑$540 range per share, as detailed in the filing. According to the transaction summary, these moves result in a net disposition of 10,000 shares. The filing notes that the option exercise and subsequent share sales were carried out under a pre-arranged Rule 10b5-1 trading plan entered into by Edgemond on October 31, 2025.
United Therapeutics Chairperson and CEO Martine Rothblatt reported an exercise-and-sell transaction in company stock. She exercised stock options for 9,500 shares of common stock at a strike price of $146.03 per share, then sold the same 9,500 shares in multiple open-market trades at weighted average prices in the mid-$540 range.
The activity occurred on June 4, 2026 under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025, which is scheduled to continue until the earlier of the exercise of 1,734,410 stock options expiring on March 15, 2027 or December 31, 2026. The filing also lists indirect holdings in common stock through various family trusts and the reporting person’s spouse.
UNITED THERAPEUTICS Corp executive vice president and general counsel Paul A. Mahon reported an exercise-and-sell transaction in company stock. He exercised stock options covering 8,300 shares of common stock at $146.03 per share and, on the same date, sold 8,300 shares in a series of open-market trades at prices generally around $543–$549 per share. The activity was carried out under a pre-arranged Rule 10b5-1 trading plan that Mahon entered into on August 11, 2025. Following these transactions, he directly holds 45,172 shares of UNITED THERAPEUTICS common stock.
United Therapeutics Chairperson & CEO Martine Rothblatt reported a same-day option exercise and share sale in United Therapeutics Corp. common stock. She exercised 9,500 stock options at $146.03 per share and sold 9,500 shares in multiple open‑market trades, at prices generally in the mid‑$540s to low‑$550s per share, under a pre‑arranged Rule 10b5‑1 trading plan adopted on November 7, 2025. Following these transactions, she directly owned 50,013 common shares and also reported additional indirect holdings through various family trusts and her spouse.
Paul Mahon reported an intended sale of 8,300 shares of common stock via a stock option exercise to the issuer for cash on 06/04/2026. The filing also lists multiple prior sales of 8,300 shares on dates from 03/05/2026 through 05/21/2026 with disclosed sale proceeds.
United Therapeutics Chairperson and CEO Martine Rothblatt reported an exercise-and-sale transaction in company stock. On June 2, 2026, she exercised stock options to acquire 9,500 shares of common stock at an exercise price of $146.03 per share, then sold 9,500 shares in open-market transactions at prices disclosed in ranges between $535.16 and $543.40 per share under a pre-arranged Rule 10b5-1 trading plan.
Following these transactions, Rothblatt owns 50,013 shares of United Therapeutics common stock directly. In addition, family trusts and a spouse account hold indirect positions, including trusts with 324,443, 249,108, 45,596, and 8,902 shares and a spouse-held position of 166 shares.
The footnotes state that the trading plan, adopted on November 7, 2025, will continue until the earlier of the exercise of 1,734,410 stock options that expire on March 17, 2027, or December 31, 2026.